The immune landscape of esophageal cancer

TX Huang, L Fu - Cancer communications, 2019 - Springer
Esophageal cancer (EC) seriously threatens human health, and a promising new avenue for
EC treatment involves cancer immunotherapy. To improve the efficacy of EC immunotherapy …

Prognostic role of tumor-infiltrating lymphocytes in gastric cancer: A systematic review and meta-analysis

X Cao, Y Kang, P Tai, P Zhang, X Lin, F Xu… - Clinics and Research in …, 2024 - Elsevier
Background To analyze the relationship between tumor-infiltrating lymphocytes (TILs)
subtypes and infiltration locations and the prognosis of gastric cancer (GC) patients …

High systemic immune-inflammation index is an adverse prognostic factor for patients with gastroesophageal adenocarcinoma

G Jomrich, M Paireder, I Kristo, A Baierl… - Annals of …, 2021 - journals.lww.com
Objective: The aim of this study was to determine the clinical role of the systemic immune-
inflammation index in patients with resectable adenocarcinoma of the gastroesophageal …

Immune checkpoint blockade therapy

T Wieder, T Eigentler, E Brenner, M Röcken - Journal of Allergy and Clinical …, 2018 - Elsevier
Immune checkpoints are accessory molecules that either promote or inhibit T-cell activation.
Two inhibitory molecules, cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell …

[HTML][HTML] Cooperation between chemotherapy and immunotherapy in gastroesophageal cancers

M Davern, J Lysaght - Cancer letters, 2020 - Elsevier
Gastroesophageal cancers (GOCs) represent some of the most common cancers globally
and are linked with poor survival rates. The current standard of care includes multimodal …

[HTML][HTML] Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype …

AEM van Erp, YMH Versleijen-Jonkers… - Oncotarget, 2017 - ncbi.nlm.nih.gov
In order to explore the potential of immune checkpoint blockade in sarcoma, we investigated
expression and clinical relevance of programmed cell death-1 (PD-1), programmed death …

Distinct antibody clones detect PD-1 checkpoint expression and block PD-L1 interactions on live murine melanoma cells

C Martins, M Silva, E Rasbach, P Singh, Y Itoh… - Scientific reports, 2022 - nature.com
Monoclonal antibodies (abs) targeting the programmed cell death 1 (PD-1) immune
checkpoint pathway have revolutionized tumor therapy. Because T-cell-directed PD-1 …

Immunotherapy for esophageal cancer: a 2019 update

D Schizas, N Charalampakis, C Kole, KS Mylonas… - …, 2020 - Taylor & Francis
Esophageal cancer remains a global health concern with a dismal prognosis and an
estimated 5-year survival rate of approximately 10–15%. Immunotherapy is a novel …

Blockade of programmed cell death protein 1 (PD-1) in Sézary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation

I Saulite, D Ignatova, YT Chang, C Fassnacht… - …, 2020 - Taylor & Francis
ABSTRACT Sézary syndrome (SS) is an aggressive leukemic variant of cutaneous T-cell
lymphoma (L-CTCL) that arises from malignant clonally derived skin-homing CD4+ T cells …

The immunoscore is a superior prognostic tool in stages II and III colorectal cancer and is significantly correlated with programmed death-ligand 1 (PD-L1) expression …

T Yomoda, T Sudo, A Kawahara, T Shigaki… - Annals of Surgical …, 2019 - Springer
Background In colorectal cancer (CRC), the indication for immune checkpoint inhibitors is
determined by the microsatellite instability status of the tumors. However, an optimal …